RxDoctor Payments DataLook up a doctor →

Catherine Ham, MD

Neurology · Richmond, VANPI 1609073139

Payments from drug & device makers

$602,532in general payments, 2019–2025

Across 695 payments — averaging $866.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$239K
  • Amgen$144K
  • Lundbeck LLC$92K
  • Biohaven Pharmaceuticals, Inc.$67K
  • Teva Pharmaceuticals USA, Inc.$44K
  • Pfizer$15K
  • plus $513 from 3 others

What the payments were for

  • Consulting fees$16,7133%
  • Speaking & faculty fees$527,59888%
  • Travel & lodging$44,9817%
  • Food & beverage$12,9372%
  • Education$3030%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)279$239,038
Amgen145$144,421
Lundbeck LLC97$91,592
Biohaven Pharmaceuticals, Inc.86$67,311
Teva Pharmaceuticals USA, Inc.55$44,285
Pfizer22$15,372
AstraZeneca(2 entities)4$249
Lilly USA, LLC5$174
Impel Pharmaceuticals Inc.2$90

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$602,532 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$8,326
Medicare patients
69
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm108$99,057
UbrelvyUbrogepant71$93,770
Nurtec OdtRimegepant Sulfate74$88,964
QuliptaAtogepant47$67,311
Aimovig AutoinjectorErenumab-Aooe38$30,574
Emgality SyringeGalcanezumab-Gnlm19$23,934
Ajovy AutoinjectorFremanezumab-Vfrm11$13,779
ZavzpretZavegepant Hcl11$11,687
Sumatriptan Succinate41$2,455
Topiramate42$623
Amitriptyline Hcl23$555
RizatriptanRizatriptan Benzoate24$515
Gabapentin17$248
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine26$240
Nortriptyline Hcl15$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$239,038$161,080118 claims
PfizerNurtec Odt, Zavzpret$15,372$100,65185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →